细胞色素P4502D6基因多态性和药物相互作用

中国临床药理学与治疗学 ›› 2006, Vol. 11 ›› Issue (4): 369-374.

细胞色素P4502D6基因多态性和药物相互作用

李芹, 王睿¹

中国海洋大学海洋药物与食品研究所, 青岛266003, 山东;
¹中国人民解放军总医院临床药理研究室, 北京100853

收稿日期:2005-12-14 修回日期:2006-03-29 出版日期:2006-04-26 发布日期:2020-12-08
通讯作者: 王睿, 女, 研究员, 博士生导师, 主要从事临床药理学研究。Tel:010-66939409 　E-mail:wangrui301@vip.sina.com
作者简介:李芹, 女, 博士研究生, 主要从事临床药理学研究。Tel:010-66937909 　E-mail:liqinql@163.com
基金资助:
国家863 计划资助项目(№ 2004AA2Z3765)

Genetic polymorghism of CYP2D6 and drug interactions

LI Qin, WANG Rui¹

Marine Drug and Food Institute, Pcean University of China, Qingdao 266003;
¹Chinese PLA General Hospital, Beijing 100853

Received:2005-12-14 Revised:2006-03-29 Online:2006-04-26 Published:2020-12-08

摘要/Abstract

摘要： 细胞色素P4502D6(CYP2D6) 是一种重要的P450 系氧化代谢酶, 参与多种重要药物的代谢。CYP2D6 具有基因多态性, 对药物的代谢呈现明显的个体差异。而且CYP2D6 能被多种药物竞争性抑制和诱导, 药物联用时易产生相互作用。本文从CYP2D6 的基因多态性与代谢表型、底物竞争作用、代谢酶的诱导和抑制等方面, 探讨CYP2D6 基因多态性与药物相互作用的关系。

关键词: CYP2D6, 基因多态性, 药物相互作用, 抑制, 诱导

Abstract: As one of major cytochrome P450s, CYP2D6 is responsible for many important drugs' metabolism.The genetic polymorphism of CYP2D6 is the basis of significant individual variability in the metabolism of drugs.Meanwhile, many drugs can influence the activity of CYP2D6 by competitive inhibition or induction, which is easy to cause interaction in coadministration.So we will investigate the relations of genetic polymorphism of CYP2D6 to drug interactions from such aspects as phenotype, competitive inhibition of substrates, induction or inhibition of CYP2D6.

Key words: CYP2D6, genetic polymorphism, drug interactions, inhibition, induction

中图分类号:

R969.2

李芹, 王睿. 细胞色素P4502D6基因多态性和药物相互作用[J]. 中国临床药理学与治疗学, 2006, 11(4): 369-374.

LI Qin, WANG Rui. Genetic polymorghism of CYP2D6 and drug interactions[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(4): 369-374.

参考文献

1 孙忠实, 朱珠.药物代谢性相互作用研究进展[J].医药世界, 2004;8:60-1
2 付良青, 吴德政.细胞色素P4502D6 的研究进展[J].中国临床药理学杂志, 2000;16:453-7
3 http://www.imm.ki.se/CYPallele/cyp2d6.htm
4 Vandel P, Haffen E, Nezelof S.Clomipramine, fluoxetine and CYP2D6 metabolic capacity in depressed patients[J].Hum Psychopharmacol, 2004;19:293-8
5 Eap CB, Sirot EJ, Baumann P.Therapeutic monitoring of antidepressants in the era of pharmacogenetics studies[J].Ther Drug Monit, 2004;26:152-5
6 Brosen K.Some aspects of genetic polymorphism in the biotransformation of antidepressants[J].Therapie, 2004;59:5-12
7 Eap CB, Bondolfi G, Zullino D, Savary-Cosendai L, Powell-Golay K, Kosel M, et al.Concentrations of the enantiomers of fluoxetine and norfluoxetine after multiple doses of fluoxetine in cytochrome P4502D6 poor and extensive metabolizers[J].J Clin Psychopharmacol, 2001;21:330-4
8 Vandel S, Bertschy G, Baumann P, Bouquet S, Bonin B, Francois T, et al.Fluvoxamine and fluoxetine:interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients[J].Pharmacol Res, 1995;31:347-53
9 Yoon YR, Cha IJ, Shon JH, Kim KA, Cha YN, Jang IJ, et al. Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6 ＊ 10 genotype of Korean subjects[J].Clin Pharmacol Ther, 2000;67:567-76
10 Kari L, Steven DB, Harry B, Juha R, Jutta H, Harry S, et al. Effect of the novel anxiolytic drug deramciclane on cytochrome P450 2D6 activity as measured by desipramine pharmacokinetics [J].Eur J Clin Pharmacol, 2004;59:893-8
11 Brosen K, Hansen JG, Nielsen KK, Sindrup SH, Gram LF.Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine[J].Eur J Clin Pharmacol, 1993;44:349-55
12 Tsuyoshi F, Isamu Y, Yuko N, Qian Z, Masako O, Kanji T, et al.Effect of CYP2D6＊10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers[J].Br J Clin Pharmacol, 1999;47:450-3
13 Albers LJ, Reist C, Vu RL.Effect of venlafaxine on imipramine metabolism[J].Psychiatry Res, 2000;96:235-43
14 Taguchi M, Nozawa T, Kameyama T, Inoue H, Takesono C, Mizukami A, et al.Effect of CYP2D6 ＊ 10 on pharmacokinetic variability of routinely administered metoprolol in middle-aged and elderly Japanese patients[J].Eur J Clin Pharmacol, 2003; 59:385-8
15 Chen B, Cai WM.Influence of CYP2D6 ＊ 10B genotype on pharmacokinetics of propafenone enantiomers in Chinese subjects [J].Acta Pharmacol Sin, 2003;24:1277-80
16 杨露芳, 诸骏仁.普罗帕酮的药物相互作用[J].中华心血管病杂志, 1997;25:480-2
17 Giessmann T, Modess C, Hecker U, Zschiesche M, Dazert P, Kunert-Keil C, et al.CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects[J].Clin Pharmacol Ther, 2004; 75:213-22
18 Graff DW, Williamson KM, Pieper JA, Carson SW, Adams KF Jr, Cascio WE, et al.Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients[J].J Clin Pharmacol, 2001;41:97-106
19 Grozinger M, Dragicevic A, Hiemke C, Shams M, Muller MJ, Hartter S.Melperone is an inhibitor of the CYP2D6 catalyzed Odemethylation of venlafaxine[J].Pharmacopsychiatry, 2003;36: 3-6
20 Spina E, Avenoso A, Scordo MG, Ancione M,Madia A, Gatti G, et al.Inhibition of Risperidone Metabolism by Fluoxetine in PatientsWith Schizophrenia:A Clinically Relevant Pharmacokinetic Drug Interaction[J].J Clin Psychopharmacol, 2002;22:419-23
21 Taylor D.Pharmacokinetic interactions involving clozapine[J]. Br J Psychiatry, 1997;171:109-12
22 Ereshefsky L, Riesenman C, Lam YW.Antidepressant drug interactions and the cytochrome P450 system.The role of cytochrome P450 2D6[J].Clin Pharmacokinet, 1995;29:10-8
23 Alfaro CL, Lam YW, Simpson J.CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study:intraindividual variability and plasma concentration correlations[J].J Clin Pharmacol, 2000;40:58-66
24 Hamelin BA, Bouayad A,Methot J, Jobin J, Desgagnes P, Poirier P, et al.Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity[J].Clin Pharmacol Ther, 2000;67:466-77
25 Etienne LM, Marie YB, Bettina AH.Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans[J].J Clin Psychopharmacol, 2001;21:175-84
26 Eap CB, Lessard E, Baumann P, Brawand-Amey M, Yessine MA, Hara GO, et al.Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans[J].Pharmacogenetics, 2003; 13:39-47
27 Hsu A,Granneman GR, Bertz RJ.Ritonavir.Clinical pharmacokinetics and interactions with other anti-HIV agents[J].Clin Pharmacokinet, 1998;35:275-91
28 Kelly DV, Beique LC, Bowmer MI.Extrapyramidal symptoms with ritonavir/indinavir plus risperidone[J].Ann Pharmacother, 2002;36:827-30
29 Jover F, Cuadrado JM, Andreu L, Merino J.Reversible coma caused by risperidone-ritonavir interaction[J].Clin Neuropharmacol, 2002;25:251-3
30 Cvetkovic RS, Goa KL.Lopinavir/ritonavir:a review of its use in the management of HIV infection[J].Drugs, 2003;63:769-802
31 王娜, 刘会臣, 候艳宁.细胞色素P4502D6 与药物代谢 [J].中国临床药理学杂志, 2001;17:308-12
32 Spina E, Avenoso A, Campo GM.Phenobarbital induces the 2-hydroxylation of desipramine[J].Ther Drug Monit, 1996;18:60-4

[1]	郝潇, 赵美, 王文静, 张飞飞, 刘惠良, 党懿, 李树仁, 齐晓勇. 钠-葡萄糖共转运体2抑制剂在急性心肌梗死应用研究进展[J]. 中国临床药理学与治疗学, 2023, 28(7): 824-831.
[2]	李青华, 赵艳, 赵海港, 高朋飞, 徐炳欣. ABCB1 G2677T 基因多态性检测在缺血性脑卒中患者应用阿托伐他汀降脂治疗中的价值[J]. 中国临床药理学与治疗学, 2023, 28(6): 633-640.
[3]	王娟, 刘维英, 叶育才, 付文丽, 张莎, 李乐萍. 去甲肾上腺素再摄取抑制剂联合抗毒蕈碱剂治疗阻塞性睡眠呼吸暂停的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(6): 714-720.
[4]	何雪茹, 李颖, 马银玲, 付裕豪, 荀雪姣, 董占军. 索拉非尼和达格列净在大鼠体中药代动力学相互作用研究[J]. 中国临床药理学与治疗学, 2023, 28(5): 498-507.
[5]	朱丽, 魏兵, 廖世峨, 张超, 郑晓宇, 刘亚军. 药物代谢酶细胞色素P450单核苷酸多态性影响哮喘儿童吸入皮质醇激素疗效研究[J]. 中国临床药理学与治疗学, 2023, 28(5): 536-543.
[6]	张志英, 靳秀红, 张小宁, 张向峰, 罗青林, 张松林. TBX21和ADCY9多态性在儿童哮喘发生发展中的临床研究[J]. 中国临床药理学与治疗学, 2023, 28(4): 407-412.
[7]	张明康, 马彦荣, 靳永文, 周燕, 崔睿睿, 武新安. 药源性急性间质性肾炎的临床研究进展[J]. 中国临床药理学与治疗学, 2023, 28(4): 419-428.
[8]	沈嘉庆, 刘毅. 酪氨酸激酶2抑制剂治疗斑块型银屑病机制与临床研究进展[J]. 中国临床药理学与治疗学, 2023, 28(3): 323-330.
[9]	刘南玉, 岳红梅, 宋佩佩, 魏继芳, 魏雅倩, 谢莹莹, 王嘉琪. PDE4抑制剂作为肺纤维化的治疗靶点[J]. 中国临床药理学与治疗学, 2023, 28(3): 355-360.
[10]	刘璐, 石雨菲, 何庆烽, 徐凤艳, 王鲲, 蔡卫民, 相小强. 群体模型分析方法评估基因多态性对药物PK/PD的影响[J]. 中国临床药理学与治疗学, 2023, 28(11): 1275-1282.
[11]	黄好, 贾虹, 王晓霜, 张鹭, 蒋华. 负载MAGE-A3抗原的树突状细胞与细胞因子诱导杀伤细胞共培养对子宫内膜癌肿瘤干细胞及恶性进展的影响[J]. 中国临床药理学与治疗学, 2023, 28(1): 42-50.
[12]	黄小明, 杜野, 林少明, 沈观乐. 呼吸道微生态对晚期非小细胞肺癌患者接受PD-1抑制剂单药治疗疗效影响的探索性研究[J]. 中国临床药理学与治疗学, 2023, 28(1): 66-74.
[13]	沈畅, 艾可龙, 胡长平. 低氧诱导因子1信号通路调控低氧性肺动脉高压研究进展[J]. 中国临床药理学与治疗学, 2023, 28(1): 114-120.
[14]	王爽, 刘嘉, 张月丽. POR*28基因多态性与中国肾移植患者他克莫司稳定剂量的相关性研究[J]. 中国临床药理学与治疗学, 2022, 27(9): 991-997.
[15]	张可心, 贾文静, 崔佳文, 敖路遥, 周芳, 王广基, 刘嘉莉. 第三代EGFR酪氨酸激酶抑制剂在非小细胞肺癌临床治疗中的应用及研究进展[J]. 中国临床药理学与治疗学, 2022, 27(9): 1016-1030.